Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotine for Cognitive Remediation in Schizophrenia
NCT02069392Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of nicotine polacrilex in schizophrenia and schizoaffective disorder (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: MATRICS Consensus Cognitive Battery Composite Score at 14 weeks. Started Jan 2015; status: completed.
02
Drugs
nicotine polacrilex
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02069392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069392.